Drug Profile
APL 180
Alternative Names: APL180Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Cardiovascular therapies
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary disorders